source
- Two promising heart drugs fail, podcast examines whyThe latest episode of The Readout LOUD looked at two experimental therapies that had been billed as the next breakthrough in treating heart disease. The discussion highlighted how billions of dolla…
- Shionogi's mid-stage stroke drug redasemtide fails, while Bayer's Hyrnuo receives expanded NSCLC labelShionogi reported that its experimental stroke therapy redasemtide did not achieve the primary endpoint in a mid-stage clinical trial, marking a setback for the company’s neurology pipeline. The f…